Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845286 | 0.86 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL5845566 | 0.86 | CXCR2 (0.81) | CXCR2CXCR1 | |
| SCHEMBL5847562 | 0.85 | CXCR2 (0.76) | CXCR2CXCR1 | |
| SCHEMBL5846271 | 0.85 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL21983376 | 0.85 | CXCR2 (0.72) | CXCR2CXCR1 | |
| SCHEMBL5846794 | 0.85 | CXCR2 (0.80) | CXCR2CXCR1 | |
| SCHEMBL5846095 | 0.85 | CXCR2 (0.71) | CXCR2CXCR1 | |
| SCHEMBL6850672 | 0.85 | CXCR2 (0.84) | CXCR2CXCR1 | |
| SCHEMBL5847566 | 0.84 | CXCR2 (0.74) | CXCR2CXCR1 | |
| SCHEMBL5846543 | 0.84 | CXCR2 (0.70) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030004189-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LTD. (GB) | 2003-01-02 | — | — | US | disclosed |
| WO-2002053544-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | DARWIN DISCOVERY LTD. (GB) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | CXCR2 1447/4885CXCR1 4122/4885 |
| US-20030004189-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | CXCR2 1447/4885CXCR1 4122/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | CXCR2 1447/4885CXCR1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.